Abstract
Plastic polarization of macrophage is involved in tumorigenesis. M1‐polarized macrophage mediates rapid inflammation, entity clearance and may also cause inflammation‐induced mutagenesis. M2‐polarized macrophage inhibits rapid inflammation but can promote tumour aggravation. ω‐3 long‐chain polyunsaturated fatty acid (PUFA)‐derived metabolites show a strong anti‐inflammatory effect because they can skew macrophage polarization from M1 to M2. However, their role in tumour promotive M2 macrophage is still unknown. Resolvin D1 and D2 (RvD1 and RvD2) are docosahexaenoic acid (DHA)‐derived docosanoids converted by 15‐lipoxygenase then 5‐lipoxygenase successively. We found that although dietary DHA can inhibit prostate cancer in vivo, neither DHA (10 μmol/L) nor RvD (100 nmol/L) can directly inhibit the proliferation of prostate cancer cells in vitro. Unexpectedly, in a cancer cell‐macrophage co‐culture system, both DHA and RvD significantly inhibited cancer cell proliferation. RvD1 and RvD2 inhibited tumour‐associated macrophage (TAM or M2d) polarization. Meanwhile, RvD1 and RvD2 also exhibited anti‐inflammatory effects by inhibiting LPS‐interferon (IFN)‐γ‐induced M1 polarization as well as promoting interleukin‐4 (IL‐4)‐mediated M2a polarization. These differential polarization processes were mediated, at least in part, by protein kinase A. These results suggest that regulation of macrophage polarization using RvDs may be a potential therapeutic approach in the management of prostate cancer.
Keywords: M1 macrophage, M2a macrophage, PKA, resolvin D, tumour‐associated macrophage
1. INTRODUCTION
Macrophage possesses multiple functions in immunomodulation and tissue repair. Plastic polarization bestows the exact role of macrophage in diverse biological process. According to the Th1‐Th2 classification, macrophage polarization can be roughly divided into M1 and M2 types. 1 Classically activated M1 macrophage can be found in tissues suffering acute inflammation or be experimentally induced by lipopolysaccharide (LPS) and interferon gamma (IFN‐γ). M1 macrophage plays a pro‐inflammatory role by increasing the concentrations of superoxide anions, oxygen radicals and nitrogen radicals as well as secreting inflammatory factors including interleukin 1β (IL‐1β), IL‐6 and tumour necrosis factor α (TNF‐α). 2 , 3 On the one hand, M1 macrophage can execute pathogen clearance and promote tumour cell killing via activating CD8+ T cell and NK cell 4 , 5 , 6 , 7 , 8 ; on the other hand, M1 macrophage also causes inflammation and involves various pathological process such as insulin resistance and inflammation‐associated mutagenesis. 9 , 10 Activated M2 macrophage can be divided into various subsets including M2a, M2b, M2c and M2d (aka. tumour‐associated macrophage, TAM). 4 Although these M2 subsets share some markers (eg CD206 and CD163) and immunosuppressive functions, different subsets are induced by different mechanisms and have diverse physiological functions. 11 , 12 M2a, induced by IL‐4 and/or IL‐13, is the mostly studied M2 subset. Immunosuppressive M2a macrophage expresses scavenger receptors and secretes IL‐10, transforming growth factor β (TGF‐β) and C‐C motif chemokine ligand 17 (CCL17). 4 , 13 The immunomodulatory functions of M2b and M2c are similar to those of M2a but have distinct inducers (immune complex for M2b and glucocorticoids for M2c). 4 , 14 In general, M2a, M2b and M2c tend to attenuate inflammation and are considered as physiologic inhibitors to M1 macrophage. 15 Different from above‐mentioned three M2 subsets, TAM is a highly heterogeneous collection with diverse activation modes and markers among different tumour tissues. The exact inducer of TAM is still not clear and might include the combinations among vascular endothelial growth factors (VEGFs), TGF‐β, IL‐4, CCL2, colony‐stimulating factors (CSFs) and some extracellular matrix components. Therefore, common methods to acquire certain TAM are to isolate them from target tumour tissues in vivo or from the cancer cell‐macrophage co‐culture system in vitro. Despite the heterogeneity, different TAMs play a similar tumour promotive role in the microenvironment via secreting immunosuppressive factors (eg IL‐10), angiogenic factors (eg VEGFs) and growth factors (eg EGF). 7 , 16
Docosahexaenoic acid (DHA) which is a dietary ω‐3 polyunsaturated fatty acid (PUFA) exhibits remarkable anti‐inflammatory effect, and this effect largely attributes to its oxidation products including resolvin, maresin and protectin. 17 Resolvin D (RvD) comprises a series of lipoxygenase metabolites from DHA and in which RvD1 and RvD2 get the most attentions. 15‐lipoxygenase (ALOX15) or aspirin‐modified cyclooxygenase‐2 (COX‐2) converts DHA to 17‐hydroxy DHA (17‐HDHA) and then 5‐lipoxygenase (ALOX5) metabolized 17‐HDHA to RvD1, RvD2, RvD3 and RvD4. 18 In general, RvDs exhibit anti‐inflammatory effects via modulating the activation of monocytes, macrophages, T lymphocyte and epithelial cell. 19 , 20 , 21 A switch of M1 to M2 polarization and consequent decrease of pro‐inflammatory mediators were reported as the critical mechanism of RvDs’ anti‐inflammatory function. 17 , 19 , 22 , 23 RvD1 can induce higher levels of reparative macrophages expressing typical M2‐like marker, CD206, in heart failure mice. 24 RvDs inhibit murine abdominal aortic aneurysm formation and increase M2 macrophage polarization 17 , 19 , 22 , 23 and may also improve cognition in mild cognitive impairment patients. 19 , 23
As tumour environment tends to induce a M2‐like TAM, blocking TAM polarization could be a potential anti‐tumour therapeutic strategy. 25 RvD was reported to suppress tumour growth by enhancing clearance of debris via macrophage phagocytosis 26 and to reduce the number of cancer mediator‐induced CD11b+Ly6G− myeloid cells. 27 In addition, some studies have revealed the anti‐tumour effect of ω‐3 PUFAs is ALOX5‐ or ALOX15‐dependent. 28 , 29 , 30 In light of these literature, we wonder whether RvD can affect TAM polarization. In this study, we found that RvDs had the opposite effect on M2a and TAM (M2d), namely RvD1 and RvD2 promoted M2a but inhibited TAM polarization. This process depended on RvD induced up‐regulation of PKA pathway.
2. MATERIALS AND METHODS
2.1. Pten‐knock out mice and diets
Prostate‐specific Pten knockout (Pten −/−) mice were generated as described previously. 31 All procedures were approved by the ethics committee of Jiangnan University. The prostate tissue was weighed, embedded into paraffin, cut into 5‐micron‐thick sections and stained with haematoxylin and eosin (H&E). Immunohistochemical staining was performed to detect the expression of total macrophages marker. The operation was according to previous studies of our laboratory. 31 , 32
Diet formulas were from the custom animal diet laboratory of the Animal Resources Program at Wake Forest University (US). According to our previous researches, 31 , 32 the ω‐6 diet was based on a typical American diet consisting of an ω‐6 to ω‐3 ratio of 40:1, 397 kcal/100 g with 30% of energy from fat, 50% from carbohydrates and 20% from proteins. And the isocaloric ω‐3 diet had an ω‐6 to ω‐3 ratio of 1:1.
2.2. Cell culture
Human prostate cancer cell line PC3 (CRL1435; ATCC), 22RV1 (CRL2505; ATCC), monocytic leukaemia cell line THP‐1 (TIB‐202; ATCC) and mouse fibroblast cell L929 (CCL1; ATCC) were provided by Shanghai Institute of Cell Biology, Chinese Academy of Sciences, Shanghai, China. PC3 and 22RV1 were maintained in RPMI 1640 supplemented with 5% (v/v) foetal bovine serum (FBS, 10099141; Gibco). THP‐1 was grown in RPMI 1640 medium supplemented with 5% (v/v) FBS, 200 μmol/L glutamine (Thermo Fisher Scientific) and 0.2 μmol/L β‐mercaptoethanol (Sigma). L929 cells were maintained in Dulbecco's modification of Eagle's medium (DMEM) supplemented with 5% (v/v) FBS.
Bone marrow‐derived macrophage (BMDM) was isolated from mouse tibia according to Spring Harbor Protocols. 33 In brief, femur and tibia bones are collected from 6 to 8 weeks male C57BL6/J mice and bone marrow cells were flushed out using Hank's buffer. After lysis of red blood cells. BMDM cells are cultured in BMDM growth medium (70% DMEM complete medium, 30% L929 cell supernatant).
2.3. Macrophage polarization
Differentiation of THP‐1 cells into M0, M1 or M2a macrophages was performed as previously described. 34 Briefly, THP‐1 cells were differentiated into M0 macrophages by incubation with 100 nmol/L phorbol 12‐myristate 13‐acetate (PMA, P8139; Sigma) for 24 hours. Then, the cells were transferred to PMA‐free media for another 24 hours to obtain resting macrophages (M0). These cells were then polarized to M1 macrophages by treating with 100 ng/mL LPS (L4516, Sigma) and 20 ng/mL hIFN‐γ (285‐IF; R&D systems) for 72 hours or to M2a macrophages by treating with 20 ng/mL hIL‐4 (204‐IL; R&D systems) for 72 hours. For BMDM polarization, cells were similarly stimulated with LPS/mIFN‐γ or mIL‐4. To obtain TAM, M0 THP‐1 cells were incubated with supernatant of cancer cells or co‐cultured with cancer cells for 3 days. During TAM polarization, media with or without RvD were renewed at day 2 and collected at day 3 as conditioned medium (CM) or RvDCM, respectively. RvD1 (872993‐05‐0) and RvD2 (810668‐37‐2) were purchased from Cayman chemical. For co‐culture assay, transwell inserts with 0.4 μm pore size were chosen to avoid cell shuttle.
2.4. Western blot
Proteins were separated by SDS‐PAGE, transferred onto an NC membrane (45‐004‐001, GE Healthcare) and then probed with relevant antibodies (Table S2) at 4°C overnight. HRP‐labelled goat anti‐mouse or anti‐rabbit IgG secondary antibodies were used for ECL detection (WBKLS0500; Sigma).
2.5. RNA extraction and quantitative real‐time PCR (qPCR)
Total RNA was isolated using TRIZOL reagent (15596018, Thermo Fisher Scientific) according to the manufacturer's protocol. Then, reverse transcription was performed using Prime Script® RT reagent Kit with gDNA Eraser (PR047A; Takara). Real‐time PCR was performed on CFX96 Real‐Time System (BIO‐RAD) using SYBR Green PCR master mix (4367659; Thermo Fisher Scientific). Primers used for qPCR were listed in Table S1. All experiments were performed in triplicate, and the mRNA level of GAPDH was chosen as the internal reference. Fold changes of target genes were calculated using the 2(‐ΔΔCT).
2.6. Flow cytometry analysis
Cells were detached with trypsin and re‐suspended in DPBS as single cell suspensions. Then, the suspensions were incubated with human or mouse FcR Blocking Reagent (Miltenyi Biotec) for 30 minutes at 4°C. Surface antigens were then stained directly, while intracellular antigens were stained after membrane permeabilization. Buffers and antibodies used for flow cytometry analysis were listed in Table S2. Isotype‐matched controls were included. Stained cells were analysed on an Attune NxT flow cytometer (Thermo Fisher Scientific).
2.7. MTT assay
To determine cell proliferation, MTT (Thiazolyl Blue Tetrazolium Bromide) assay was performed. In brief, medium was replaced by 0.5 mg/mL MTT (M5655; Sigma) in serum‐free medium. MTT solution was discarded after 4 hours incubation under normal culture conditions, and insoluble formazan was dissolved by DMSO. Values of OD570 and OD630 were recorded to evaluate cell count.
2.8. ELISA
Sandwich ELISA was performed to detect cytokines in TAM supernatant. The supernatant was directly used for ELISA in a 96‐well plate without dilution or freeze‐thaw. All operations were performed in accordance with manufacturer's protocol. After adding stop solution, plates were read immediately using a microplate reader set to 450 and 540 nm (reference wavelength). The concentration of cytokines was calculated according to the standard curve. Three independent experiments were performed. The information of kits can be found in Table S2.
2.9. Statistics
All data were analysed using GraphPad Prism 6 software. The results from animal experiments were shown as mean ± SEM, and the results from cultured cell were shown as mean ± SD (n ≥ 3). Two‐tailed Student's t test was used for the statistical comparison of two groups. One‐way analysis of variance (ANOVA); then, Tukey's test was used for multiple comparisons. P < .05 was considered significant. When using letters to show statistical differences, there was NO significant difference between groups marked with the same letter and there were significant differences between any two groups marked with different letters.
3. RESULTS
3.1. RvD1 and RvD2 reduce the ability of macrophage to stimulate cancer cell proliferation
Prostate‐specific knockout of Pten (Pten −/−) induces prostatic intraepithelial neoplasia (PIN) and prostate cancer in mice. 35 To verify the effect of dietary DHA on mouse prostate cancer, we generated two diets with high ω‐6 PUFAs (mainly provided by Safflower seed oil) and high ω‐3 PUFAs (mainly provided by fish oil with 70% DHA). Compared with ω‐6 PUFA diet which induced significant extension of malignant cells, ω‐3 PUFA diet attenuated the pathogenesis of prostate cancer in Pten −/− mice (Figure 1A). And, the weight of the prostate was also reduced in mice with ω‐3 PUFA diet (Figure 1B). Our previous researches also indicated that ω‐3 PUFA diet reduced Ki67 expression and caspase 3 cleavage in the prostate of Pten −/− mice. 31 , 32 However, as the active component, direct addition of DHA into culture could not inhibit cancer cell proliferation under our experimental conditions (Figure 1C). Thus, we reasoned that the metabolites of ω‐3 PUFA and the involvement of tumour microenvironment may mediate ω‐3 PUFA induced tumour inhibition.
ALOX5 and ALOX15 which convert DHA to resolvin Ds (RvDs) were highly expressed in prostate cancer. 36 And they were also expressed in prostate cancer from mice fed with both ω‐6 and ω‐3 PUFA diet (Figure S1A). RvDs showed their anti‐tumour effects against some cancer cells. 27 , 37 , 38 Unexpectedly, neither RvD1 nor RvD2 inhibited proliferation of prostate cancer cells directly (Figure 1E).
Macrophage which has a M2‐like phenomenon is an important tumour promotive component in tumour microenvironment. We found that ω‐3 PUFA diet strongly decreased the infiltration of total macrophage (Figure 1F). Moreover, referred to CD68 (a total macrophage marker), CD163 expression (an M2‐like macrophage marker) was also inhibited by ω‐3 PUFA diet (Figure 1G). These suggested that tumour‐associated macrophage (TAM) may involve with Pten −/− tumour development. As expected, proliferation of cancer cells was significantly promoted by the co‐cultured THP‐1 macrophage. Interestingly, DHA and RvDs effectively reverse this process although they cannot directly inhibit tumour growth (Figure 1C‐E). These results suggest that macrophage co‐cultured with cancer cell can promote the proliferation of cancer cells in which RvD1 and RvD2 can dampen the oncogenic crosstalk between cancer cells and macrophages.
3.2. RvD1 and RvD2 suppress TAM polarization
Cancer cells generate a tumour‐promoting microenvironment in which TAM is both the ‘victim’ (polarization stage) and the ‘perpetrator’ (effect stage). 39 In order to determine the mechanism of RvDs’ effect, we separated these two stages. Primed THP‐1 was treated by supernatant of cancer cells (polarization stage), and then, macrophage‐conditioned medium was transferred to newly seeded cancer cells (effect stage) (Figure 2A). Consistent with the co‐culture results, TAM‐conditioned medium (CM) promoted the growth of cancer cells and RvD also diminished the stimulatory activity of CM. Of note, only adding RvD1 and RvD2 in the polarization stage but not the effect stage inhibits the proliferation of cancer cells (Figure 2B). At the same time, cell growth curve showed that CM accelerated the growth of tumour cells, while RvDCM could alleviate this effect (Figure 2C). Thus, RvD1 and RvD2 affected TAM polarization rather than TAM’s effect.
TAM expresses some of M2 macrophage markers including CD206. 40 Meanwhile, TAM expresses highly VEGFA and epidermal growth factor (EGF) and promotes angiogenesis and carcinogenesis. 41 , 42 We found that the supernatant of PC3 prostate cancer cells promoted the expression of CD206, VEGFA and EGF in THP‐1 indicating the polarization of TAM. However, RvD1 and RvD2 reversed the changes of CD206, VEGFA and EGF expression (Figure 2D‐F). Interestingly, we also found that COX‐2, a hallmark of M1 macrophage, was down‐regulated in TAM and could also be partially reversed by RvD (Figure 2E). We also noted that the supernatant of M0 THP‐1 had no effect on the growth of tumour cells, and the effect of RvDs on M0 THP‐1 was trifling (Figure S1B‐D). These results suggest that RvD1 and RvD2 can inhibit TAM polarization, and this provides a potential mechanism for their anti‐tumour effect.
3.3. RvD1 and RvD2 promote M2a polarization
TAM aka. M2d macrophage is a subset of M2 macrophage. 43 Thus, it is necessary to explore if resolvins’ inhibitory effect on TAM polarization could affect other anti‐inflammatory subsets of M2 macrophage, for example M2a. IL‐4 can induce a classical M2a polarization with an increased expression of CD204, CD163, TGF‐β, IL‐10, CCL17 and CD206. 44 , 45 , 46 Contrary to TAM, RvD1 and RvD2 up‐regulated the expression of these M2a markers and factors (Figure 3A,B). Similar results were observed not only in THP‐1 macrophage but also in BMDM. RvD1 and RvD2 increased the markers of M2a in BMDM including Fizz1 and Arg1 (Figure 3C,D). These results indicate that RvD1 and RvD2 preferentially inhibit polarization of TAM (M2d) but promote polarization of M2a macrophage.
3.4. RvD1 and RvD2 inhibit M1 polarization
We also evaluated the role of RvD1 and RvD2 on M1 macrophage polarization. It is well documented that LPS and IFN‐γ induce THP‐1 cells to M1 macrophage with up‐regulation of C‐C chemokine receptor type 7 (CCR7), inducible nitric oxide synthases (iNOS), TNF‐α, C‐X‐C motif chemokine ligand 3 (CXCL3), IL‐6 and CXCL9. 47 , 48 , 49 RvD1 and RvD2 treatments reduced all these markers except CXCL9 (Figure 4A,B). Similarly, the M1 polarization of BMDM was also inhibited by RvD1 and RvD2 (Figure 4C,D). These results indicate that RvD1 and RvD2 can significantly inhibit the polarization of M1 macrophages supporting their anti‐inflammatory role.
3.5. RvD1 and RvD2 modulate macrophage polarization via PKA pathway
The results above raised a question how RvDs regulate different macrophage subsets at the same time. There are three known RvD receptors, GPR32 and ALX/FPR2 for RvD1 and GPR18 for RvD2. 50 , 51 These receptors are expressed on macrophage (Figure S1E,F) and regulate cell function via cAMP/PKA pathway (ALX/FPR2, GPR32 and GPR18), 52 , 53 , 54 PI3K/AKT pathway (ALX/FPR2 and GPR18) 55 , 56 , 57 and PKC pathway (ALX/FPR2 and GPR32). 58 , 59 Therefore, we explored the classical activation of PKA, AKT and PKC pathways during RvD involved macrophage polarization. Total and phosphorylated PKA‐C (Thr197) were reduced in M1 while up‐regulated in M2a and TAM macrophages (Figure 5A). AKT had no significant change among M0, M1, M2a and TAM macrophages while both total and phosphorylated PKCβ were increased in M1, M2a and TAM macrophages (Figure 5A). Up‐regulated PKA and p‐PKA might be inhibitory to M1 but promotive to M2 polarization. In TAM polarization, however, effect of RvD on PKA was less pronounced (Figure 5A). Therefore, it seems that the differential effect of RvDs on various subsets of macrophages is via its regulation of PKA pathway. In view of the potential role of the PKA pathway, we explored the effect of PKA inhibition on macrophage polarization. Upon H‐89 (a PKA inhibitor) treatment, the effects of RvDs on M1, M2a and TAM polarization were all reversed except RvD2 regulated M2a (Figure 5B,C). These data suggest that PKA pathway plays an important role in macrophage polarization. The regulation of RvD on macrophage polarization partly depends on PKA pathway.
4. DICUSSION
Previous studies have reported that RvDs induce a switch of M1 polarization to M2 polarization, 17 , 19 , 22 , 23 while their role on TAM polarization is still unclear. Our study found that RvD1 and RvD2 can regulate the polarization of M1, M2a and prostate cancer‐associated TAM. Besides the co‐culture system, we adopted a medium transfer model and identified that RvD1 and D2 affected macrophage directly rather than tumour cells. This finding suggests that RvD1 and D2 can exert their anti‐tumour effect on multiple stages during tumorigenesis. The inhibition of M1 and promotion of M2a macrophage attenuate the mutagenic inflammation before tumour initiation and the modulation of TAM reduces the support for tumour cell proliferation.
It is generally believed that the signal pathway activated by RvDs originate from their receptors. RvD1 interacts with both GPR32 and ALX/FPR2 while RvD2 binds to GPR18, 50 , 51 even though, ligands of these receptors are not limited to resolvins. However, signalling pathway activated by RvD may be different from those activated by other ligands. For example, GPR32 and GPR18 are both considered as the Gi type G protein‐coupled receptor, 53 , 54 but RvD1 and RvD2 have been repeatedly proven to up‐regulate cAMP. 53 , 60 Here, we also found that RvD1 and RvD2 could increase both phosphorylated and total PKA in M1 and M2a macrophages. This suggests that RvDs may activate their receptors through recruiting Gs type rather than generally reported Gi type effectors.
Cyclic AMP‐PKA pathway is a critical determinant in M1‐M2a polarization, potentially regulating the direction of macrophage polarization. 61 In this study, we showed that both total PKA and phosphorylated PKA were down‐regulated in M1 macrophage whereas up‐regulated in M2a and TAM. IFN‐γ‐signal transducer and activator of transcription 1 (STAT1) pathway determines M1 polarization and IL‐4‐STAT6 pathway leads to M2a polarization. 62 PKA regulatory IIα subunit (PRKAR2A) can bind to the transmembrane domain of IFN‐γ receptor and suppressed Janus kinase 2 (Jak2)‐STAT1 pathway. In contrast, PKA activates cAMP response element‐binding protein (CREB) and up‐regulates the transcription of M2 polarization elicited by IL‐4. 63 , 64 RvD restored reduced PKA in M1 and amplified enhanced PKA in M2a. This provides a potential mechanism to explain why RvD can inhibit M1 and promote M2a polarization at the same time.
Inducers of TAM may include cytokines (IL4, IL‐13 and IL‐10), lipid mediators (PGE2), chemokines (CCL2 and CCL22), growth factors (CSF1, VEGFs and EGF), immune complex and various extracellular molecules (ROS, L‐arginine, PD‐1, ANG2, HMGB1 and even low oxygen). 65 TAM also has some molecular characteristics of both M1 and M2 including low NF‐κB activation, high hypoxia‐inducible factor (HIF)‐1α, high iNOS and high Arg‐1. 62 , 66 It is unclear though what factor(s) from prostate cancer cells initiates TAM polarization and how activation (activation degree, activation site and even subcellular localization) of PKA promotes the polarization process. However, our study observed a slight but stable increase of PKA in TAM and we also found that PKA inhibitor, H‐89, can reduce TAM polarization. These suggest that activation of PKA pathway is necessary, but not sufficient for TAM polarization and RvD’s effect can be multi‐targeted. The activity of PKA depends on not only its activation but also its subcellular localization. A‐kinase anchoring proteins (AKAPs) is the controller of PKA localization. Microtubule‐binding protein MAP2 which is an AKAP can be significantly up‐regulated by ω‐3 PUFA rather than ω‐6 PUFA. 67 , 68 This provides another potential mechanism by which RvDs regulate MAP2 (or other AKAPs) and alter the subcellular localization of PKA so that influence the signal transduction downstream of PKA without affecting the activation of PKA itself.
CONFLICT OF INTEREST
The authors declared that they have no conflicts of interest to this work.
Supporting information
ACKNOWLEDGEMENTS
This research was supported by the National Key Research and Development Program of China (2017YFD0400200), the National Natural Science Foundation of China Grants No. 31771539, Key Research and Development Program of Jiangsu Province (BE2018624) and National First‐class Discipline Program of Food Science and Technology (JUFSTR20180101).
Shan K, Feng N, Cui J, et al. Resolvin D1 and D2 inhibit tumour growth and inflammation via modulating macrophage polarization. J Cell Mol Med. 2020;24:8045–8056. 10.1111/jcmm.15436
Kai Shan and Ninghan Fen are contributed equally.
DATA AVAILABILITY STATEMENT
The data used to support this study are available from the corresponding author upon request.
REFERENCES
- 1. Murray PJ, Wynn TA. Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol. 2011;89(4):557‐563. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Fairweather D, Cihakova D. Alternatively activated macrophages in infection and autoimmunity. J Autoimmun. 2009;33(3–4):222‐230. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Sindrilaru A, Peters T, Wieschalka S, et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J Clin Invest. 2011;121(3):985‐997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Shapouri‐Moghaddam A, Mohammadian S, Vazini H, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233(9):6425‐6440. [DOI] [PubMed] [Google Scholar]
- 5. Medina‐Contreras O, Geem D, Laur O, et al. CX3CR1 regulates intestinal macrophage homeostasis, bacterial translocation, and colitogenic Th17 responses in mice. J Clin Invest. 2011;121(12):4787‐4795. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Ma J, Liu L, Che G, Yu N, Dai F, You Z. The M1 form of tumor‐associated macrophages in non‐small cell lung cancer is positively associated with survival time. BMC Cancer. 2010;10:112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Pathria P, Louis TL, Varner JA. Targeting tumor‐associated macrophages in cancer. Trends Immunol. 2019;40(4):310–327. [DOI] [PubMed] [Google Scholar]
- 8. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117(5):1155‐1166. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219‐246. [DOI] [PubMed] [Google Scholar]
- 10. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860‐867. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. He H, Xu J, Warren CM, et al. Endothelial cells provide an instructive niche for the differentiation and functional polarization of M2‐like macrophages. Blood. 2012;120(15):3152‐3162. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Georgoudaki AM, Prokopec KE, Boura VF, et al. Reprogramming tumor‐associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep. 2016;15(9):2000‐2011. [DOI] [PubMed] [Google Scholar]
- 13. Carneros D, Santamaria EM, Larequi E, et al. Cardiotrophin‐1 is an anti‐inflammatory cytokine and promotes IL‐4‐induced M2 macrophage polarization. FASEB J. 2019;33(6):7578–7587. [DOI] [PubMed] [Google Scholar]
- 14. Hao NB, Lu MH, Fan YH, Cao YL, Zhang ZR, Yang SM. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol. 2012;2012:948098. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009;27:451‐483. [DOI] [PubMed] [Google Scholar]
- 16. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39‐51. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity. 2014;40(3):315‐327. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Serhan CN. Discovery of specialized pro‐resolving mediators marks the dawn of resolution physiology and pharmacology. Mol Aspects Med. 2017;58:1‐11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Pope NH, Salmon M, Davis JP, et al. D‐series resolvins inhibit murine abdominal aortic aneurysm formation and increase M2 macrophage polarization. FASEB J. 2016;30(12):4192‐4201. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Chiurchiu V, Leuti A, Dalli J, et al. Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses. Sci Transl Med. 2016;8(353):353ra111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Odusanwo O, Chinthamani S, McCall A, Duffey ME, Baker OJ. Resolvin D1 prevents TNF‐alpha‐mediated disruption of salivary epithelial formation. Am J Physiol Cell Physiol. 2012;302(9):C1331‐C1345. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Gu Z, Lamont GJ, Lamont RJ, Uriarte SM, Wang H, Scott DA. Resolvin D1, resolvin D2 and maresin 1 activate the GSK3beta anti‐inflammatory axis in TLR4‐engaged human monocytes. Innate Immun. 2016;22(3):186‐195. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Famenini S, Rigali EA, Olivera‐Perez HM, et al. Increased intermediate M1–M2 macrophage polarization and improved cognition in mild cognitive impairment patients on omega‐3 supplementation. FASEB J. 2017;31(1):148‐160. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Halade GV, Kain V, Serhan CN. Immune responsive resolvin D1 programs myocardial infarction‐induced cardiorenal syndrome in heart failure. FASEB J. 2018;32(7):3717‐3729. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Ni Gabhann J, Hams E, Smith S, et al. Btk regulates macrophage polarization in response to lipopolysaccharide. PLoS One. 2014;9(1):e85834. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Sulciner ML, Serhan CN, Gilligan MM, et al. Resolvins suppress tumor growth and enhance cancer therapy. J Exp Med. 2018;215(1):115‐140. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Ye Y, Scheff NN, Bernabe D, et al. Anti‐cancer and analgesic effects of resolvin D2 in oral squamous cell carcinoma. Neuropharmacology. 2018;139:182‐193. [DOI] [PubMed] [Google Scholar]
- 28. Berquin IM, Edwards IJ, Chen YQ. Multi‐targeted therapy of cancer by omega‐3 fatty acids. Cancer Lett. 2008;269(2):363‐377. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Sapieha P, Stahl A, Chen J, et al. 5‐Lipoxygenase metabolite 4‐HDHA is a mediator of the antiangiogenic effect of omega‐3 polyunsaturated fatty acids. Sci Transl Med. 2011;3(69):69ra12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Hu Y, Sun H, O'Flaherty JT, Edwards IJ. 15‐Lipoxygenase‐1‐mediated metabolism of docosahexaenoic acid is required for syndecan‐1 signaling and apoptosis in prostate cancer cells. Carcinogenesis. 2013;34(1):176‐182. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Berquin IM, Min Y, Wu R, et al. Modulation of prostate cancer genetic risk by omega‐3 and omega‐6 fatty acids. J Clin Invest. 2007;117(7):1866‐1875. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Wang S, Wu J, Suburu J, et al. Effect of dietary polyunsaturated fatty acids on castration‐resistant Pten‐null prostate cancer. Carcinogenesis. 2012;33(2):404‐412. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Weischenfeldt J, Bone PB. Marrow‐derived macrophages (BMM): isolation and applications. CSH Protoc. 2008;2008(12):pdb:prot5080. [DOI] [PubMed] [Google Scholar]
- 34. Murray PJ. Macrophage polarization. Annu Rev Physiol. 2017;79:541‐566. [DOI] [PubMed] [Google Scholar]
- 35. Wang S, Gao J, Lei Q, et al. Prostate‐specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003;4(3):209‐221. [DOI] [PubMed] [Google Scholar]
- 36. Nie D. Cyclooxygenases and lipoxygenases in prostate and breast cancers. Front Biosci. 2007;12:1574‐1585. [DOI] [PubMed] [Google Scholar]
- 37. Lee HJ, Park MK, Lee EJ, Lee CH. Resolvin D1 inhibits TGF‐beta1‐induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32. Int J Biochem Cell Biol. 2013;45(12):2801‐2807. [DOI] [PubMed] [Google Scholar]
- 38. Kuang H, Hua X, Zhou J, Yang R. Resolvin D1 and E1 alleviate the progress of hepatitis toward liver cancer in long‐term concanavalin A‐induced mice through inhibition of NF‐kappaB activity. Oncol Rep. 2016;35(1):307‐317. [DOI] [PubMed] [Google Scholar]
- 39. Yang M, McKay D, Pollard JW, Lewis CE. Diverse functions of macrophages in different tumor microenvironments. Cancer Res. 2018;78(19):5492‐5503. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Bohrer LR, Schwertfeger KL. Macrophages promote fibroblast growth factor receptor‐driven tumor cell migration and invasion in a CXCR2‐dependent manner. Mol Cancer Res. 2012;10(10):1294‐1305. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16(2):91‐102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Hughes R, Qian BZ, Rowan C, et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res. 2015;75(17):3479‐3491. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Duluc D, Corvaisier M, Blanchard S, et al. Interferon‐gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor‐associated macrophages. Int J Cancer. 2009;125(2):367‐373. [DOI] [PubMed] [Google Scholar]
- 44. Kubota T, Inoue M, Kubota N, et al. Downregulation of macrophage Irs2 by hyperinsulinemia impairs IL‐4‐induced M2a‐subtype macrophage activation in obesity. Nat Commun. 2018;9(1):4863. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677‐686. [DOI] [PubMed] [Google Scholar]
- 46. Nikolic‐Paterson DJ, Wang S, Lan HY. Macrophages promote renal fibrosis through direct and indirect mechanisms. Kidney Int Suppl (2011). 2014;4(1):34‐38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Shiratori H, Feinweber C, Luckhardt S, et al. THP‐1 and human peripheral blood mononuclear cell‐derived macrophages differ in their capacity to polarize in vitro. Mol Immunol. 2017;88:58‐68. [DOI] [PubMed] [Google Scholar]
- 48. Genin M, Clement F, Fattaccioli A, Raes M, Michiels C. M1 and M2 macrophages derived from THP‐1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer. 2015;15:577. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49. Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH. The identification of markers of macrophage differentiation in PMA‐stimulated THP‐1 cells and monocyte‐derived macrophages. PLoS One. 2010;5(1):e8668. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50. Chiang N, Dalli J, Colas RA, Serhan CN. Identification of resolvin D2 receptor mediating resolution of infections and organ protection. J Exp Med. 2015;212(8):1203‐1217. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Krishnamoorthy S, Recchiuti A, Chiang N, et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci USA. 2010;107(4):1660‐1665. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52. Mottola G, Chatterjee A, Wu B, Chen M, Conte MS. Aspirin‐triggered resolvin D1 attenuates PDGF‐induced vascular smooth muscle cell migration via the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) pathway. PLoS One. 2017;12(3):e0174936. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Chiang N, Barnaeva E, Hu X, et al. Identification of chemotype agonists for human resolvin D1 receptor DRV1 with pro‐resolving functions. Cell Chem Biol. 2019;26(2):244‐254. e4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Martin AL, Steurer MA, Aronstam RS. Constitutive activity among orphan class‐A G protein coupled receptors. PLoS One. 2015;10(9):e0138463. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. Zheng S, Wang Q, D'Souza V, et al. ResolvinD1 stimulates epithelial wound repair and inhibits TGF‐beta‐induced EMT whilst reducing fibroproliferation and collagen production. Lab Invest. 2018;98(1):130‐140. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56. Wang Q, Zheng X, Cheng Y, et al. Resolvin D1 stimulates alveolar fluid clearance through alveolar epithelial sodium channel, Na, K‐ATPase via ALX/cAMP/PI3K pathway in lipopolysaccharide‐induced acute lung injury. J Immunol. 2014;192(8):3765‐3777. [DOI] [PubMed] [Google Scholar]
- 57. Grabiec U, Hohmann T, Ghadban C, et al. Protective effect of N‐arachidonoyl glycine‐GPR18 signaling after excitotoxical lesion in murine organotypic hippocampal slice cultures. Int J Mol Sci. 2019;20(6):1266. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Cattaneo F, Parisi M, Ammendola R. Distinct signaling cascades elicited by different formyl peptide receptor 2 (FPR2) agonists. Int J Mol Sci. 2013;14(4):7193‐7230. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59. Dartt DA, Hodges RR, Serhan CN. Immunoresolvent resolvin D1 maintains the health of the ocular surface. Adv Exp Med Biol. 2019;1161:13‐25. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Botten N, Hodges RR, Li D, et al. Resolvin D2 elevates cAMP to increase intracellular [Ca(2+)] and stimulate secretion from conjunctival goblet cells. FASEB J. 2019;33(7):8468‐8478. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61. Ghosh M, Xu Y, Pearse DD. Cyclic AMP is a key regulator of M1 to M2a phenotypic conversion of microglia in the presence of Th2 cytokines. J Neuroinflammation. 2016;13:9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62. Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage m1–m2 polarization balance. Front Immunol. 2014;5:614. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Kong D, Shen Y, Liu G, et al. PKA regulatory IIalpha subunit is essential for PGD2‐mediated resolution of inflammation. J Exp Med. 2016;213(10):2209‐2226. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64. Wu HY, Tang XQ, Liu H, Mao XF, Wang YX. Both classic Gs‐cAMP/PKA/CREB and alternative Gs‐cAMP/PKA/p38beta/CREB signal pathways mediate exenatide‐stimulated expression of M2 microglial markers. J Neuroimmunol. 2018;316:17‐22. [DOI] [PubMed] [Google Scholar]
- 65. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012;33(3):119‐126. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66. Yang L, Zhang Y. Tumor‐associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10(1):58. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67. Zhong H, Sia GM, Sato TR, et al. Subcellular dynamics of type II PKA in neurons. Neuron. 2009;62(3):363‐374. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68. Katakura M, Hashimoto M, Okui T, Shahdat HM, Matsuzaki K, Shido O. Omega‐3 polyunsaturated Fatty acids enhance neuronal differentiation in cultured rat neural stem cells. Stem Cells Int. 2013;2013:490476. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data used to support this study are available from the corresponding author upon request.